Join our coalition and help us create a future in which epidemics are no longer a threat to humanity.
Lives were saved between 2010 and 2015 thanks to vaccines. (WHO, 2017)
The cost of the 2014 Ebola epidemic in west Africa. (C Huber et al, 2018)
The estimated annual global cost of moderately severe to severe pandemics (World Bank, 2017)
The average minimum cost for progressing one vaccine against each of WHO’s 11 priority epidemic infectious diseases. (D Gouglas et al, 2018)
CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum.
To date, CEPI has secured over $760 million toward its $1 billion funding target, with financial support provided by the Bill & Melinda Gates Foundation, the Wellcome Trust, the European Commission, and the governments of Australia, Belgium, Canada, Ethiopia, Germany, Japan, Norway and the UK.
Since our launch in 2017, CEPI has announced a number of calls for funding proposals. The first call supports candidate vaccines against Middle East Respiratory Syndrome coronavirus (MERS-CoV), Nipah virus, and Lassa virus. The second call will advance rapid response vaccine platforms against unknown pathogens, known as 'Disease X'. The third call is supporting vaccines against Rift Valley fever and Chikungunya viruses. We also launched a call in October 2019, is for the development of innovative platform technologies that can be used to develop vaccines and other immunoprophylactics to rapidly respond to future outbreaks of emerging infectious diseases and “Disease X”.
Most recently, we ran a funding call to develop and manufacture already proven vaccine technology that can be used against virus behind COVID-19.
To date, CEPI has committed to investing up to $475 million in vaccine development. This includes 19 vaccine candidates against its priority pathogens (six against Lassa virus, five against MERS-CoV, four against Nipah virus, two against Chikungunya, two against Rift Valley fever) and three vaccine platforms to develop vaccines against Disease X. To assess the effectiveness of these platforms 7 additional vaccine candidates are being developed (two against influenza, one against Marburg virus, two against Rabies virus, one against Respiratory Syncytial Virus, and one against yellow fever).
Our vaccine development partners include Emergent Biosolutions, Janssen Vaccines & Prevention B.V., Imperial College London, CureVac, IDT Biologika, Inovio, the International AIDS Vaccine Initiative (IAVI), Profectus Biosciences, Themis Bioscience, Public Health Vaccines, Valneva SE, Colorado State University, PATH, Wageningen Bioveterinary Research, University of Tokyo, University of Queensland, and University of Oxford.
In addition, CEPI has announced funding for four programmes with Inovio, University of Queensland, Moderna, and Curevac, to rapidly advance the development of vaccine candidates against 2019-nCoV. GSK has also announced that it will make its established pandemic vaccine adjuvant platform technology available to enhance the development of an effective vaccine against the virus behind the disease COVID-19.
Bill and Melinda Gates Foundation
Government of Norway
Government of Japan
Government of Germany
The Wellcome Trust
Government of Australia
We create innovative partnerships between public, private, philanthropic, and civil organisations to develop vaccines against diseases with epidemic potential.
We invest in promising vaccine candidates against our priority pathogens and platform technologies that can enable rapid development of vaccines and immunoprophylactics against new and unknown pathogens. We also coordinate activities to improve our collective response to epidemics.
Learn more about our funding opportunities.
CEPI aims to invest in vaccine-based solutions that not only protect some of the most vulnerable people in the world but will also help to prevent future pandemics.
Get in touch to find out how your organisation could work with CEPI.